Abstract
After the Spanish flu pandemic, it was apparent that airborne transmission was crucial to spreading virus contagion, and research responded by producing several fundamental works like the experiments of Duguid [J. Hyg. 44:6, 1946] and the model of Wells [Am. J. Hyg., 20:611–18,1934]. These seminal works have been pillars to past and current guidelines published by health organizations. However, in about one century, understanding of turbulent aerosol transport by jets and plumes has enormously progressed and it is now time to use this body of developed knowledge. In this work, we use detailed experiments and accurate computationally-intensive numerical simulations of droplet-laden turbulent puffs emitted during sneezes in a wide range of environmental conditions. We consider the same emission – number of drops, drop size distribution and initial velocity – and we change environmental parameters as temperature and humidity, and we observe strong variation in droplets evaporation or condensation in accordance with their local temperature and humidity microenvironment. We assume that 3% of the initial droplet volume is made of non-volatile matter. Our systematic analysis confirms that droplets lifetime is always about one order of magnitude larger compared to previous predictions, in some cases up to 200 times. Finally, we have been able to produce original virus exposure maps, which can be a useful instrument for health scientists and practitioners to calibrate new guidelines to prevent short-range airborne disease transmission.
Significance Statement Violent expiratory events represent an important route for the spread of respiratory viruses, as the SARS-CoV-2 virus. We use finely-resolved experiments and simulations to quantify how the turbulent cloud of moist air exhaled during a sneeze largely increases the airborne time and the lifespan of virus-loaded droplets. By providing visualizations of the spatial distribution of the virus copies, we highlight the high infection risk associated with droplets that remain airborne in the near proximity of an infected individual. The present study aims at raising awareness among public health authorities about this infection risk, which is grossly underestimated by current guidelines.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
CINECA supercomputing center (Bologna, Italy) is gratefully acknowledged for generous allowance of computer resources under grants HP10C1XSJU. Authors gratefully acknowledge the financial support from the MSCA-ITN-EID project COMETE (813948), from PRIN project Advanced computations and experiments in turbulent multiphase flow (2017RSH3JY) and from the Research project promoted by China Scholarship Council (201806250023).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The authors report no conflict of interest.
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.